IP Library Granted Patent US 8,183,362
Granted Patent B2
US 8,183,362 · App. 11/982,425 · Granted May 22, 2012

Method and medicament for inhibiting the expression of a given gene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,362
App. No.
11/982,425
Granted
May 22, 2012
Kind
B2
Abstract

The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.

Claims (21)

1. An isolated double stranded RNA (dsRNA) comprising two separate complementary oligoribonucleotide strands,

wherein each of said strands consists of 21 nucleotides in length,

wherein the dsRNA does not comprise a full length RNA transcript of a mammalian target gene,

wherein one strand of said dsRNA is complementary to less than the full length of an RNA transcript of said mammalian target gene,

wherein said separate oligoribonucleotide strands are chemically linked to reduce dissociation as compared to non-linked oligoribonucleotide strands,

and wherein said dsRNA is capable of specifically inhibiting the expression of said mammalian target gene.

2. The dsRNA of claim 1 , wherein at least one of said oligoribonucleotide strands comprises at least one chemically modified nucleotide.

3. The dsRNA of claim 2 , wherein said chemically modified nucleotide is a 2′-modified nucleotide.

4. The dsRNA of claim 3 , wherein said 2′-modified nucleotide is a 2′-methyl substituted nucleotide.

5. The dsRNA of claim 3 , wherein said 2′-modified nucleotide is a 2′-amino substituted nucleotide.

6. The dsRNA of claim 2 , wherein said chemically modified nucleotide is a locked nucleotide.

7. A vector encoding the dsRNA of claim 1 , wherein said vector is either a plasmid vector or a viral vector.

8. A cell transformed with the vector of claim 7 .

9. The dsRNA of claim 1 , wherein said dsRNA is modified so as to be resistant to RNA degradation.

10. The dsRNA of claim 2 , wherein only one nucleotide of at least one of said oligoribonucleotide strands is a chemically modified nucleotide.

11. The dsRNA of claim 1 , wherein said dsRNA is capable of specifically inhibiting the expression of said mammalian target gene using dsRNA-mediated interference.

12. The dsRNA of claim 1 , wherein said separate oligoribonucleotide strands are chemically linked with a linker comprising a covalent linker.

13. The dsRNA of claim 12 , wherein said covalent linker is a C18 linker.

14. The dsRNA of claim 1 , wherein said separate oligoribonucleotide strands are chemically linked with a linker comprising a labile linker.

15. The dsRNA of claim 14 , wherein said labile linker is a disulfide bridge.

16. The dsRNA of claim 1 , wherein said two separate complementary strands are fully complementary to each other.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2009
From: ALNYLAM EUROPE AG
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 023070/0300 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE, WHICH IS CURRENTLY SHOWN INCORRECTLY WITH THE COUNTRY AS "MASSACHUSETTS" BUT SHOULD READ "GERMANY". PREVIOUSLY RECORDED ON REEL 020489 FRAME 0410. ASSIGNOR(S) HEREBY CONFIRMS THE THAT THE ASSIGNEE'S ADDRESS, SHOWING THE COUNTRY AS "GERMANY", IS CORRECTLY IDENTIFIED ON THE ATTACHED ORIGINAL ASSIGNMENT.. Recorded Jun 3, 2008
From: KREUTZER, ROLAND; LIMMER, STEFAN
To: RIBOPHARMA AG
Reel/Frame 021034/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2008
From: KREUTZER, ROLAND; LIMMER, STEFAN
To: RIBOPHARMA AG
Reel/Frame 020489/0410 →
CHANGE OF NAME Recorded Feb 11, 2008
From: RIBOPHARMA AG
To: ALNYLAM EUROPE AG
Reel/Frame 020493/0111 →